A safety study of KAN-101 in patients with celiac disease. The study has two parts:
1. Part A - first in human study in which patients receive a single dose of KAN-101
2. Part B - patients will receive three doses of either KAN-101 or placebo
Phase:
Phase 1
Details
Lead Sponsor:
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA